Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)-Reference-Cited by-同舟云学术

Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)

Published:2020-11 Issue:6 Volume:21 Page:520-526
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Patel Jyoti D.,Lee Ju-Whei,Carbone David P.,Wagner Henry,Shanker Anil^ORCID,de Aquino Maria Teresa P.,Horn Leora,Johnson Melissa L.,Gerber David E.,Liu Jane Jijun,Das Millie S.,Al-Nsour Mohammed Ali,Dakhil Christopher S.R.,Ramalingam Suresh,Schiller Joan H.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients;Auperin;Ann Oncol,2006

2. Therapeutic management options for stage III non-small cell lung cancer;Yoon;World J Clin Oncol,2017

3. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410;Curran;J Natl Cancer Inst,2011

4. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease;Delbaldo;Cochrane Database Syst Rev,2007

5. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma;Le Chevalier;Lung Cancer,1994

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review);Oncology Reports;2024-06-11

2. Lung cancer vaccination from concept to reality: A critical review of clinical trials and latest advances;Life Sciences;2024-06

3. Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer;European Journal of Drug Metabolism and Pharmacokinetics;2023-10-04

4. Early-Stage Lung Cancer in the Era of Precision Oncology: From Immunotherapy to Targeted Therapy;Interventional Oncology;2023

5. Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?;Current Oncology;2022-10-31